Eligible participants were 13 years of age or older, had HIV-1 infection with a CD4 count of less than 250 (the CD4 count threshold for HIV treatment eligibility at the time), had not previously received ART, and had confirmed or probable TB. The gene discussed is CD4; the disease is tuberculosis.